✦ LIBER ✦

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?

✍ Scribed by A Gabriel; O Pirk; W Kotowa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN67 Erlotinib as Second Line Treatment

✍ Santos, E.A.V.; Buschinelli, C.T.; Ferracini, M.; Pepe, C.; Estanislao, M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN104 SOCIETAL COST SAVINGS IN METASTAT

✍ S Stanisic; A Vergnenegre; C Chouaid; E Mueller; S Walzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN

✍ E Orlewska; A Szczesna; M Gyldmark; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN37 Cost Comparison of Erlotinib Versu

✍ Schwander, B.; Ravera, S.; Giuliani, G.; Nuijten, M.; Walzer, S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB